Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $30.00.

Several equities research analysts have recently weighed in on KYTX shares. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. JPMorgan Chase & Co. reduced their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th.

Institutional Investors Weigh In On Kyverna Therapeutics

Large investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio acquired a new stake in shares of Kyverna Therapeutics during the third quarter worth $28,000. Qube Research & Technologies Ltd acquired a new position in Kyverna Therapeutics in the 2nd quarter valued at $43,000. Rhumbline Advisers increased its stake in Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after buying an additional 5,694 shares during the period. Ameriprise Financial Inc. purchased a new position in Kyverna Therapeutics during the 3rd quarter worth $77,000. Finally, Bank of America Corp DE raised its position in Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares during the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Up 0.4%

KYTX stock opened at $8.08 on Friday. The company has a market cap of $499.67 million, a price-to-earnings ratio of -2.75 and a beta of 1.93. The company has a fifty day moving average price of $8.06 and a 200 day moving average price of $8.44. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. Kyverna Therapeutics has a 12 month low of $3.27 and a 12 month high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.05. Sell-side analysts expect that Kyverna Therapeutics will post -2.78 earnings per share for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.